- Home
- NKTX vs ZNTL Comparison
NKTX vs ZNTL Comparison
Compare NKTX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- ZNTL
- Stock Information
- Founded
- NKTX 2015
- ZNTL 2014
- Country
- NKTX United States
- ZNTL United States
- Employees
- NKTX N/A
- ZNTL N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- NKTX Health Care
- ZNTL Health Care
- Exchange
- NKTX Nasdaq
- ZNTL Nasdaq
- Market Cap
- NKTX 123.5M
- ZNTL 105.8M
- IPO Year
- NKTX 2020
- ZNTL 2020
- Fundamental
- Price
- NKTX $1.77
- ZNTL $1.32
- Analyst Decision
- NKTX Strong Buy
- ZNTL Buy
- Analyst Count
- NKTX 6
- ZNTL 7
- Target Price
- NKTX $14.40
- ZNTL $8.60
- AVG Volume (30 Days)
- NKTX 422.2K
- ZNTL 943.9K
- Earning Date
- NKTX 08-12-2025
- ZNTL 08-08-2025
- Dividend Yield
- NKTX N/A
- ZNTL N/A
- EPS Growth
- NKTX N/A
- ZNTL N/A
- EPS
- NKTX N/A
- ZNTL N/A
- Revenue
- NKTX N/A
- ZNTL $26,865,000.00
- Revenue This Year
- NKTX N/A
- ZNTL N/A
- Revenue Next Year
- NKTX N/A
- ZNTL N/A
- P/E Ratio
- NKTX N/A
- ZNTL N/A
- Revenue Growth
- NKTX N/A
- ZNTL N/A
- 52 Week Low
- NKTX $1.31
- ZNTL $1.01
- 52 Week High
- NKTX $8.23
- ZNTL $5.70
- Technical
- Relative Strength Index (RSI)
- NKTX 46.34
- ZNTL 47.15
- Support Level
- NKTX $1.76
- ZNTL $1.31
- Resistance Level
- NKTX $2.08
- ZNTL $1.54
- Average True Range (ATR)
- NKTX 0.11
- ZNTL 0.14
- MACD
- NKTX -0.00
- ZNTL -0.00
- Stochastic Oscillator
- NKTX 25.00
- ZNTL 31.36
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.